ProQR Therapeutics PRQR 深 沪
等待开盘 10-02 09:30:00 美东时间
1.63
-0.030
-1.81%
华盛通- 最 高1.6861
- 今 开1.66
- 成交量 196.94万股
- 最 低 1.55
- 昨 收 1.66
- 总市值 2.30亿
- 52周最高 3.10
- 市盈率 静 --
- 换手率 1.40%
- 52周最低 1.33
- 委 比 -45.05%
- 总股本 1.41亿
- 历史最高 27.60
- 量 比 3.62
- 振 幅 8.20%
- 历史最低 0.53
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.
10-01 19:28
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
ProQR Therapeutics任命Chris Hart博士为首席数据和AI官，Thomas Wolf博士为董事会AI战略顾问，以加强其AI驱动的RNA药物开发能力。Hart博士拥有超过15年人工智能和寡核苷酸药物开发经验，而Wolf博士是Hugging Face的联合创始人，该平台最近被Nvidia收购。ProQR的AI战略整合到其Axiomer RNA编辑平台，加速药物发现和优化。AX-0811是首个通过AI发现的临床项目，预计2027年初公布数据。公司计划未来12个月内发布5个临床数据读出。
09-23 12:00
ProQR to Participate in Upcoming Investor Conferences in September 2026
ProQR Therapeutics N.V. announced that its management will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8 and the 2026 Cantor Global Healthcare Conference in New York on September 9. The company is developing Axiomer™, an RNA base editing technology that uses ADAR to make specific RNA edits, potentially treating diseases caused by RNA mutations. More details are available on ProQR’s website.
09-02 12:00
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
ProQR a new buy at BoA on RNA-editing platform
Bank of America Securities has initiated coverage of ProQR Therapeutics (PRQR) at buy, saying that the company's Axiomer RNA-editing platform has been validated, supporting its pipeline. The bank has...
08-20 21:49
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8
B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $8.
08-20 20:03
ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $10.183 millio...
08-13 20:12
美股夜盘 | Republic Power涨38.76%，巨龙在线涨22.55%
Tvardi Therapeutics Inc.涨-10.80%；Dreamland涨-9.80%；有信科技涨-9.33%
07-09 08:05
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级
今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元
06-29 15:49
